Interferon beta-1b-induced postmenopausal bleeding in a patient with multiple sclerosis

Climacteric. 2016 Dec;19(6):599-600. doi: 10.1080/13697137.2016.1244666. Epub 2016 Oct 17.

Abstract

Objective: Postmenopausal bleeding must always be evaluated to rule out endometrial carcinoma, although there are many benign etiologies. There have been rare reports of premenopausal bleeding with interferon beta-1b, used to treat multiple sclerosis, but no prior reports in postmenopausal women.

Methods: Literature searches were performed using PubMed and Medline for articles with content related to premenopausal and postmenopausal bleeding while taking interferon beta-1b. The searches were restricted to the English language. Search terms included interferon beta-1b and/or uterine hemorrhage and/or vaginal bleeding and/or postmenopausal and/or menopause.

Results: The literature review found no related articles for postmenopausal bleeding while taking interferon beta-1b. We present a case of a patient with postmenopausal bleeding attributed to elevation of serum estradiol in association with interferon beta-1b therapy.

Conclusion: It is important for patients and providers to be aware of the association between postmenopausal bleeding with the use of interferon beta-1b therapy which could be due to elevated serum estradiol levels.

Keywords: Interferon-beta/adverse effects; Interferon-beta/therapeutic use; multiple sclerosis/drug therapy; postmenopausal bleeding.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Estradiol / blood
  • Female
  • Humans
  • Interferon beta-1b / adverse effects*
  • Interferon beta-1b / therapeutic use
  • MEDLINE
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Postmenopause* / blood
  • Uterine Hemorrhage / blood
  • Uterine Hemorrhage / chemically induced*

Substances

  • Interferon beta-1b
  • Estradiol